Vitiligo-like depigmentation and morpheas after specific intralymphatic immunotherapy for malignant melanoma.

Malignant melanoma and immunotherapy.

Immunotherapy for human malignant melanoma.

Intralymphatic immunotherapy.

Active-specific immunotherapy for melanoma.

Specific active immunotherapy for melanoma.

Letter: Ascites in malignant melanoma after oral BCG immunotherapy.

Active immunotherapy in malignant melanoma.

Intralymphatic immunotherapy and vaccination in mice.

Immunotherapy for malignant melanoma: a review and update.

Intestinal perforation after nivolumab immunotherapy for a malignant melanoma: a case report.

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

Melanoma-associated antigen synthesized in vitro for active specific immunotherapy.

Monocytopoiesis in malignant melanoma: untreated, during immunotherapy and chemoimmunotherapy.

Intralesional immunotherapy for melanoma.

Intratumoral immunotherapy for melanoma.

Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival.

Progress of immunotherapy in the treatment of malignant melanoma.

Immune response and non-specific immunotherapy in melanoma.

Immunotherapy for malignant glioma.

Age-specific acceleration in malignant melanoma.

Tumour regression and survival of patients with disseminated malignant melanoma treated with chemotherapy and specific active immunotherapy.

Combination immunotherapy breakthrough for melanoma.

Advances in immunotherapy for melanoma.

Metastatic melanoma and immunotherapy.

Suggest Documents

Malignant melanoma and immunotherapy.

Immunotherapy for human malignant melanoma.

Intralymphatic immunotherapy.

Active-specific immunotherapy for melanoma.

Specific active immunotherapy for melanoma.

Letter: Ascites in malignant melanoma after oral BCG immunotherapy.

Active immunotherapy in malignant melanoma.

Intralymphatic immunotherapy and vaccination in mice.

Immunotherapy for malignant melanoma: a review and update.

Intestinal perforation after nivolumab immunotherapy for a malignant melanoma: a case report.

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

Melanoma-associated antigen synthesized in vitro for active specific immunotherapy.

Monocytopoiesis in malignant melanoma: untreated, during immunotherapy and chemoimmunotherapy.

Intralesional immunotherapy for melanoma.

Intratumoral immunotherapy for melanoma.

Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival.

Progress of immunotherapy in the treatment of malignant melanoma.

Immune response and non-specific immunotherapy in melanoma.

Immunotherapy for malignant glioma.

Age-specific acceleration in malignant melanoma.

Tumour regression and survival of patients with disseminated malignant melanoma treated with chemotherapy and specific active immunotherapy.

Combination immunotherapy breakthrough for melanoma.

Advances in immunotherapy for melanoma.

Metastatic melanoma and immunotherapy.

Vitiligo-like depigmentation and morpheas after specific intralymphatic immunotherapy for malignant melanoma.

Recommend Documents

Follow Us